查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573068

支气管痉挛治疗药物市场：按治疗类型、给药途径和最终用户划分 - 全球预测 2025-2030

Bronchial Spasms Treatment Market by Treatment Type (Medications, Non-Pharmacological Treatments), Route of Administration (Inhalation, Intravenous, Oral), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年支气管痉挛治疗药物市值为2.9681亿美元，预计到2024年将达到3.0972亿美元，复合年增长率为4.38%，预计到2030年将达到4.0777亿美元。

支气管痉挛治疗市场包括各种旨在缓解气喘和慢性阻塞性肺病（COPD）等气道狭窄特征的解决方案。治疗选择范围从药物干预（如支气管扩张剂和皮质类固醇）到新的生物製药和潜在的综合疗法。由于空气污染、吸烟习惯和遗传易感性等因素，全球呼吸系统疾病的盛行率不断增加，对这些治疗的需求也随之增加。支气管痉挛治疗的应用对于预防医学和急性加重的治疗以改善患者的生活品质都很重要。最终使用场所包括医院、诊所和门诊诊所，而便携式吸入设备的进步也使家庭治疗变得流行。市场的关键成长要素包括给药系统的技术创新、支持性医疗保健政策以及新兴国家医疗保健基础设施的扩张。个人化医疗方法和针对支气管痉挛特定途径的新型治疗方法的开发存在巨大的潜在机会。然而，高昂的研发成本、严格的监管要求以及学名药的广泛使用给品牌药收益带来压力，给市场成长带来挑战。此外，复杂的治疗方法导致的患者依从性问题也是一个障碍。为了利用成长，公司可以在数位健康解决方案等领域进行创新，透过提醒和即时监控来提高患者的依从性，或投资于更有效的吸入机制的研发。与高科技公司的合作可以增强治疗的个人化以及对患者反应模式的资料驱动洞察。儘管竞争激烈，但我们对负担得起且易于获得的治疗方法的关注，以及专注于研发和分销的战略伙伴关係关係，提供了持续的竞争优势并推动市场扩张。

主要市场统计
基准年[2023] 2.9681亿美元
预测年份 [2024] 30972万美元
预测年份 [2030] 40077万美元
复合年增长率（%） 4.38%

市场动态：快速发展的支气管痉挛治疗市场的关键市场洞察

供需的动态交互作用正在改变支气管痉挛治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球气喘和慢性阻塞性肺病盛行率上升
    • 增加政府支出和医疗保健工作
    • 提高对支气管痉挛及其对健康影响的认识
  • 市场限制因素
    • 治疗费用高昂以及药品销售的严格规定
  • 市场机会
    • 製药公司与研究机构之间的策略联盟
    • 吸入装置、雾化器和支气管痉挛治疗的创新
  • 市场挑战
    • 与支气管痉挛治疗相关的副作用

波特的五力：驾驭支气管痉挛药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解支气管痉挛治疗市场的外部影响

外部宏观环境因素在塑造支气管痉挛治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解支气管痉挛治疗药物市场的竞争状况

支气管痉挛治疗药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵支气管痉挛治疗市场供应商的绩效评估

FPNV 定位矩阵是评估支气管痉挛治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘支气管痉挛治疗药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对支气管痉挛治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球气喘和慢性阻塞性肺病盛行率上升
      • 扩大政府支出和医疗保健措施
      • 提高对支气管痉挛及其对健康影响的认识
    • 抑制因素
      • 治疗费用高，药物释放监管严格
    • 机会
      • 製药公司与研究机构的策略伙伴关係
      • 吸入器、雾化器和支气管痉挛治疗的创新
    • 任务
      • 与支气管痉挛治疗相关的副作用
  • 市场区隔分析
    • 治疗类型：用于即时缓解和长期管理的药物的使用正在增加，以改善患者的生活品质。
    • 最终用户：由于方便且易于维护而更喜欢居家照护环境的消费者。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的支气管痉挛治疗药物市场

  • 药品
    • 支气管扩张剂
    • 皮质类固醇
    • 白三烯调节剂
    • 肥大细胞稳定剂
    • 甲基黄嘌呤类
  • 非药物治疗
    • 氧气疗法
    • 呼吸復健

第七章支气管痉挛治疗药物市场：依给药途径

  • 吸入
  • 静脉
  • 口服
  • 皮下的

第八章支气管痉挛治疗药物市场：依最终使用者分类

  • 门诊手术中心
  • 家庭护理设置
  • 医院/诊所
  • 研究/学术机构

第九章北美和南美支气管痉挛治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太支气管痉挛治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲支气管痉挛治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Verona Pharma 的 Otuvaile 获得 FDA核准，成为首个新型吸入性 COPD 治疗药物
    • Viatris 和 Quindeva 推出了 Breyna，这是 FDA核准的非专利Symbicort，以改善气喘和慢性阻塞性肺病的治疗机会。
  • 战略分析和建议
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market was valued at USD 296.81 million in 2023, expected to reach USD 309.72 million in 2024, and is projected to grow at a CAGR of 4.38%, to USD 400.77 million by 2030.

The market for bronchial spasms treatment encompasses a variety of solutions aimed at alleviating the constriction of airways characteristic of conditions such as asthma and chronic obstructive pulmonary disease (COPD). Treatment options range from pharmaceutical interventions-like bronchodilators and corticosteroids-to emerging biologics and possible integrative therapies. The necessity of these treatments is heightened by the increasing global prevalence of respiratory ailments due to factors such as air pollution, smoking habits, and genetic predispositions. Applications of bronchial spasm treatments are critical for both preventative care and the management of acute exacerbations to improve patient quality of life. End-use settings include hospitals, clinics, and outpatient services, while home-based treatments also gain traction with advancements in portable inhalation devices. Key growth influencers in the market include technological innovations in drug delivery systems, supportive healthcare policies, and the growing healthcare infrastructure in emerging economies. Significant potential opportunities lie in personalized medicine approaches and the development of novel therapies targeting specific pathways involved in bronchial spasms. However, market growth is challenged by high R&D costs, stringent regulatory requirements, and the prevalence of generic alternatives dampening brand-name revenues. Additionally, patient compliance issues due to complex treatment regimens present hurdles. To capitalize on growth, firms could innovate in areas such as digital health solutions that ensure better patient adherence through reminders and real-time monitoring, or invest in R&D for more efficient inhaler mechanisms. Collaboration with tech companies could enhance treatment personalization and data-based insights into patient response patterns. Despite the competitive landscape, a focus on affordable and accessible treatments, along with strategic partnerships focusing on R&D and distribution, can provide a sustained competitive edge and foster market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 296.81 million
Estimated Year [2024] USD 309.72 million
Forecast Year [2030] USD 400.77 million
CAGR (%) 4.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of asthma and COPD globally
    • Increasing government spending and healthcare initiatives
    • Growing awareness regarding bronchial spasms and their impact on health
  • Market Restraints
    • High costs associated with treatment and stringent regulations regarding the release of drugs
  • Market Opportunities
    • Strategic partnerships between pharma companies and research institutions
    • Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
  • Market Challenges
    • Adverse effects associated with bronchial spasms treatments

Porter's Five Forces: A Strategic Tool for Navigating the Bronchial Spasms Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchial Spasms Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchial Spasms Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchial Spasms Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchial Spasms Treatment Market

A detailed market share analysis in the Bronchial Spasms Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchial Spasms Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchial Spasms Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchial Spasms Treatment Market

A strategic analysis of the Bronchial Spasms Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchial Spasms Treatment Market, highlighting leading vendors and their innovative profiles. These include Amphastar Pharmaceuticals, Inc, Bayer AG, C.H. Boehringer Sohn AG & Co. KG, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Grifols, S.A., Lybrate, Inc., Merck KGaA, Novartis AG, Orion Corporation, Pfizer Inc, Temple University Health System, Inc., Teva Pharmaceutical Industries Ltd, Vectura Group Ltd by Philip Morris International Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Non-Pharmacological Treatments. The Medications is further studied across Bronchodilators, Corticosteroids, Leukotriene Modifiers, Mast Cell Stabilizers, and Methylxanthines. The Non-Pharmacological Treatments is further studied across Oxygen Therapy and Pulmonary Rehabilitation.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, Oral, and Subcutaneous.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of asthma and COPD globally
      • 5.1.1.2. Increasing government spending and healthcare initiatives
      • 5.1.1.3. Growing awareness regarding bronchial spasms and their impact on health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with treatment and stringent regulations regarding the release of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic partnerships between pharma companies and research institutions
      • 5.1.3.2. Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with bronchial spasms treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Rising usage of medications for immediate relief and long-term management to improve patient quality of life
    • 5.2.2. End User: Consumer preference for homecare settings due to convenience and ease of maintenance
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchial Spasms Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bronchodilators
    • 6.2.2. Corticosteroids
    • 6.2.3. Leukotriene Modifiers
    • 6.2.4. Mast Cell Stabilizers
    • 6.2.5. Methylxanthines
  • 6.3. Non-Pharmacological Treatments
    • 6.3.1. Oxygen Therapy
    • 6.3.2. Pulmonary Rehabilitation

7. Bronchial Spasms Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral
  • 7.5. Subcutaneous

8. Bronchial Spasms Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Homecare Settings
  • 8.4. Hospitals & Clinics
  • 8.5. Research & Academic Institutes

9. Americas Bronchial Spasms Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bronchial Spasms Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bronchial Spasms Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Verona Pharma ohtuvayre gains FDA approval as first novel inhaled COPD treatment
    • 12.3.2. Viatris and Kindeva launch FDA-approved generic Symbicort, Breyna, to enhance asthma and COPD treatment accessibility
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amphastar Pharmaceuticals, Inc
  • 2. Bayer AG
  • 3. C.H. Boehringer Sohn AG & Co. KG
  • 4. CHIESI Farmaceutici S.p.A.
  • 5. Cipla Limited
  • 6. GlaxoSmithKline plc
  • 7. Grifols, S.A.
  • 8. Lybrate, Inc.
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Orion Corporation
  • 12. Pfizer Inc
  • 13. Temple University Health System, Inc.
  • 14. Teva Pharmaceutical Industries Ltd
  • 15. Vectura Group Ltd by Philip Morris International Inc.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHIAL SPASMS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIAL SPASMS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023